



Editor's Welcome

Dear colleagues!

In the 11th issue of the International Heart and Vascular Disease Journal, there are leading article, review, original articles and the results of two important scientific events.

The leading article of the issue is dedicated to the review of clinical studies of efficacy and safety of a new group of lipid-lowering drugs – proprotein convertase subtilisin/kexin type 9 inhibitors. European guidelines for dyslipidemia treatment of 2016 give indications for use of this new group of lipid-lowering medicines.

Two articles are included into the «Review articles» section. The first of them discusses the results of international studies of glucose-lowering drugs' cardiological safety. Authors from three Russian scientific schools participated in preparation of this article. The second review article observes the data about relation between periodontal disease and cardiovascular pathology.

In "Original articles" of the 11th issue section we published three papers. In the first article a group of authors estimates the risk of atrial fibrillation development in patients with metabolic syndrome. The second article represents the results of major clinical and experimental study aiming to identify the connection between statins therapy and endothelial dysfunction markers in patients with evident coronary atherosclerosis. One more original work called BASTion is dedicated to the study of complex therapy's safety in patients with chronic heart failure.

The results of two major scientific events are published in the 11th issue of the Journal. Annual congress of the European Society of Cardiology that involved more than 30000 specialists from 106 countries has been successfully held in Rome, Italy, on August 27-31, 2016. It included more than 500 scientific sessions in 150 different fields, including new clinical guidelines and 28 clinical studies "Hot Line".

It is known that annual Russian National Congress of Cardiology was held in Ekaterinburg, Russia, on September 20-23, 2016. Scientific program included 169 meetings. The questions of development strategies and the role of the Society in a new system of medical postgraduate education were discussed during the plenary meeting.

I invite everybody to collaborate with the journal. We are waiting for your original papers, review articles, discussions, and opinions about problems, treatment and prophylaxis recommendations.

Rafael G. Oganov

Editor-in-Chief

President of the "Cardioprogress" Foundation